MicroRNA and hepatocellular carcinoma: Biology and prognostic significance

Minerva Gastroenterologica e Dietologica

Volumn 57, Issue 3, 2011, Pages 257-271

  Milazzo, M ^a   Fornari, F ^a   Gramantieri, L ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Carcinoma, hepatocellular; Hepatitis; MicroRNAs

Indexed keywords

CASPASE; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 122; MICRORNA 199; MICRORNA 21; MICRORNA 221; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN P21; RNA; SCATTER FACTOR RECEPTOR; SOMATOMEDIN; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CLASSIFICATION; CANCER GROWTH; CANCER INVASION; CANCER TISSUE; CELL CYCLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; IN VITRO STUDY; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; METASTASIS; MICROARRAY ANALYSIS; MODULATION; ONCOGENE; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MICRORNAS; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 80755130254     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
2. Lachenmayer A, Alsinet C, Chang CY, Llovet JM. Molecular approaches to treatment of hepatocellular carcinoma. Dig Liver Dis 2010;42(Suppl 3):S264-72.
3. Chen YL, Law PY, Loh HH. Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy. Curr Med Chem Anticancer Agents 2005;5:575-89. (Pubitemid 41601056)
4. Avila MA, Berasain C, Sangro B, Prieto J. New therapies forhepatocellular carcinoma. Oncogene 2006;25:3866-84.
5. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008;135:1972-83, 1983 e1971-1911.
6. Zhou L, Huang Y, Li J, Wang Z. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol 2009;27:255-61.
7. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007;67:6092-9. (Pubitemid 47037488)
8. Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer 2009;125:345-52.
9. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007;67:8699-707. (Pubitemid 47437445)
10. Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL et al. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2010;70:5184-93.
11. Meng F, Henson R, Wehbe-Janek H, Ghoshal K.Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007;133:647-58. (Pubitemid 47187346)
12. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009;16:498-509.
13. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A 2010;107:264-9.
14. Pollak MN. Insulin-like growth factors and neoplasia. Novartis Found Symp 2004;262:84-98; discussion 98-107, 265-108.
15. Zeng C, Wang R, Li D, Lin XJ, Wei QK, Yuan Y et al. A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma. Hepatology 2010;52:1702-12.
16. Tannapfel A, Grund D, Katalinic A, Uhlmann D, Kockerling F, Haugwitz U et al. Decreased expression of p27 protein is associated with advanced tumor stage in hepatocellular carcinoma. Int J Cancer 2000;89:350-5. (Pubitemid 30620288)
17. Ito Y, Takeda T, Sakon M, Tsujimoto M, Monden M, Matsuura N. Expression of p57/Kip2 protein in hepatocellular carcinoma. Oncology 2001;61:221-5. (Pubitemid 34701537)
18. Nakai S, Masaki T, Shiratori Y, Ohgi T, Morishita A, Kurokohchi K et al. Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival. Int J Oncol 2002;20:769-75.
19. Lei PP, Zhang ZJ, Shen LJ, Li JY, Zou Q, Zhang HX. Expression and hypermethylation of p27 kip1 in hepatocarcinogenesis. World J Gastroenterol 2005;11:4587-91. (Pubitemid 41150405)
20. Csepregi A, Ebert MP, Rocken C, Schneider-Stock R, Hoffmann J, Schulz HU et al. Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma. BMC Cancer 2010;10:317.
21. Schwienbacher C, Gramantieri L, Scelfo R, Veronese A, Calin GA, Bolondi L et al. Gain of imprinting at chromosome 11p15: A pathogenetic mechanism identified in human hepatocarcinomas. Proc Natl Acad Sci U S A 2000;97:5445-9. (Pubitemid 30313738)
22. Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 2005;334:1351-8. (Pubitemid 41074723)
23. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 2007;25:387-92. (Pubitemid 47362758)
24. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2005;102:19075-80. (Pubitemid 43049568)
25. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007;120:1046-54. (Pubitemid 46214304)
26. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafre SA et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kipl. J Biol Chem 2007;282:23716-4.
27. Ie Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. Embo J 2007;26:3699-708. (Pubitemid 47236875)
28. Gillies JK, Lorimer IA. Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle 2007;6:2005-9. (Pubitemid 47327888)
29. Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer 2007;14:791-8. (Pubitemid 350074067)
30. Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA et al. MiR-221 controls CDKNlC/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008;27:5651-61.
31. Ivanovska I, Ball AS, Diaz RL, Magnus JF, Kibukawa M, Schelter JM et al. MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol 2008;28:2167-74. (Pubitemid 351429964)
32. Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B et al. MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a. Gastroenterology 2011 [In press].
33. Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S et al. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2009;69:5761-7.
34. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009;137:1005-17.
35. Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 2009;50:113-21.
36. Fabregat I, Roncero C, Fernandez M. Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int 2007;27:155-62. (Pubitemid 46680718)
37. Guo XZ, Shao XD, Liu MP, Xu JH, Ren LN, Zhao JJ et al. Effect of bax, bcl-2 and bcl-xL on regulating apoptosis in tissues of normal liver and hepatocellular carcinoma. World J Gastroenterol 2002;8:1059-62.
38. Schattenberg JM, Galle PR, Schuchmann M. Apoptosis in liver disease. Liver Int 2006;26:904-11. (Pubitemid 44323407)
39. Puthalakath H, Villunger A, O'Reilly LA, Beaumont JG, Coultas L, Cheney RE et al. Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 2001;293:1829-32. (Pubitemid 32845780)
40. Gramantieri L, Fornari F, Ferracin M, Veronese A, Sabbioni S, Calin GA et al. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res 2009;15:5073-81.
41. Sharma AD, Narain N, Handel EM, Iken M, Singhal N, Cathomen T et al. MicroRNA-221 regulates FAS-induced fulminant liver failure. Hepatology 2011 [In press].
42. Zhang C, Zhang J, Zhang A, Wang Y, Han L, You Y, et al. PUMA is a novel target of miR-221/222 in human epithelial cancers. Int J Oncol 2010;37:1621-1626.
43. Lin CJ, Gong HY, Tseng HC, Wang WL, Wu JL. miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 2008;375:315-320.
44. Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH et at. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010;51:836-45.
45. Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 2009;69:1135-42.
46. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25. (Pubitemid 37493640)
47. Benvenuti S, Comoglio PM. The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 2007;213:316-25. (Pubitemid 47509708)
48. Comoglio PM, Trusolino L. Invasive growth: from development to metastasis. J Clin Invest 2002;109:857-62. (Pubitemid 34275105)
49. Shinomiya N, Gao CF, Xie Q, Gustafson M, Waters DJ, Zhang YW et al. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res 2004;64:7962-70. (Pubitemid 39446930)
50. Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 2006;116:1582-95.
51. Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology 1997;25:862-6. (Pubitemid 27157127)
52. Kim S, Lee UJ, Kim MN, Lee EJ, Kim JY, Lee MY et al. MicroRNA miR-199a*regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2). J Biol Chem 2008;283:18158-66.
53. Henry JC, Park JK, Jiang J, Kim JH, Nagorney DM, Roberts LR et al. miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 2010;403:120-5.
54. Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett 2009;275:44-53.
55. Salvi A, Sabelli C, Moncini S, Venturin M, Arici B, Riva P et al. MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells. Febs J 2009;276:2966-82.
56. Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 2004;113:1774-83. (Pubitemid 39071669)
57. Wan XW, Jiang M, Cao HF, He YQ, Liu SQ, Qiu XH et al. The alteration of PTEN tumor suppressor expression and its association with the histopathological features of human primary hepatocellular carcinoma. J Cancer Res Clin Oncol 2003;129:100-6. (Pubitemid 36470091)
58. Wang B, Hsu SH, Majumder S, Kutay H, Huang W, Jacob ST et al. TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 2010;29:1787-97.
59. Meng F, Glaser SS, Francis H, Demorrow S, Han Y, Passarini JD et al. Functional Analysis of microRNAs in Human Hepatocellular Cancer Stem Cells. J Cell Mol Med 2011 [In press].
60. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009;28:3526-36.
61. Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009;49:1571-82.
62. Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008;47:897-907. (Pubitemid 351449681)
63. Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 2008;14:419-27. (Pubitemid 351226109)
64. Sato F, Hatano E, Kitamura K, Myomoto A, Fujiwara T, Takizawa S et al. MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria. PLoS One 2011;6:e16435.
65. Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA et al. miR-122, a mammalian liver-specific microRNA, is processed from her mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004;1:106-13.
66. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005;309:1577-81. (Pubitemid 41266486)
67. Roberts AP, Jopling CL. Targeting viral infection by microRNA inhibition. Genome Biol 2010;11:201.
68. Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006;99:671-8. (Pubitemid 44521987)
69. Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008;47:1955-63. (Pubitemid 351952843)
70. Medina R, Zaidi SK, Liu CG, Stein JL, van Wijnen AJ, Croce CM et al. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res 2008;68:2773-80. (Pubitemid 351556275)
71. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006;25:2537-45.
72. Shen Q, Cicinnati VR, Zhang X, Iacob S, Weber F, Sotiropoulos GC et al. Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. Mol Cancer 2010;9:227.
73. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. Rna 2008;14:2348-60.
74. Chang SS, Jiang WW, Smith I, Poeta LM, Begum S, Glazer C et al. MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer 2008;123:2791-7.
75. Tong AW, Nemunaitis J. Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? Cancer Gene Ther 2008;15:341-55. (Pubitemid 351693228)
76. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005;438:685-9.